Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

10.17
+0.30003.04%
Pre-market: 10.02-0.1533-1.51%09:06 EDT
Volume:2.08M
Turnover:21.39M
Market Cap:867.64M
PE:-5.83
High:10.75
Open:9.84
Low:9.68
Close:9.87
52wk High:25.77
52wk Low:7.44
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.18
T/O Rate:3.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:1.78
PE(LYR):-21.87

Loading ...

Monte Rosa Q1 FY26 net loss widens to $44.5 million; revenue falls to $4.2 million

Reuters
·
May 07

BRIEF-Monte Rosa Therapeutics Q1 Net Income USD -44.503 Million

Reuters
·
May 07

Monte Rosa Therapeutics Q1 Operating Expenses USD 54.244 Million

THOMSON REUTERS
·
May 07

Monte Rosa Therapeutics Q1 Operating Income USD -50.034 Million

THOMSON REUTERS
·
May 07

Press Release: Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 07

Monte Rosa CEO Markus Warmuth sells 5,467 shares for $103,443.57

Reuters
·
May 06

Monte Rosa grants inducement awards: options for 38,925 shares at $18.8 exercise price

Reuters
·
May 06

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 06

Monte Rosa Therapeutics announces annual shareholder meeting

Reuters
·
Apr 30

What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today

Simply Wall St.
·
Apr 21

Monte Rosa Therapeutics to present preclinical data on MRT-55811

TIPRANKS
·
Apr 20

Monte Rosa presents CCNE1 degrader data at AACR meeting

Reuters
·
Apr 20

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

GlobeNewswire
·
Apr 20

Top Executive’s Surprise Move Shakes Up Monte Rosa Therapeutics Insider Activity

TIPRANKS
·
Apr 16

Monte Rosa CEO Markus Warmuth disposes 8,000 shares for $141,120

Reuters
·
Apr 16

Top Monte Rosa Therapeutics Executive Makes Notable Insider Stock Move

TIPRANKS
·
Apr 11

Monte Rosa Chief Business & Legal Officer Philip Nickson sells 5,845 shares for $103,410

Reuters
·
Apr 11